Review
Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop
Washington (DC): National Academies Press (US); 2024 Aug 14.
- PMID: 38870332
- Bookshelf ID: NBK604279
- DOI: 10.17226/27770
Item in Clipboard
Review
Adult Attention-Deficit/Hyperactivity Disorder: Diagnosis, Treatment, and Implications for Drug Development: Proceedings of a Workshop
Excerpt
Attention deficit/hyperactivity disorder (ADHD) diagnosis and treatment among adults has increased over the past decade in the U.S. and globally. Evidence suggests adults with ADHD may be more likely to develop a substance use disorder, and there are concerns that nonmedical use of prescription stimulants could lead to misuse, overdose, or toxicity. In December 2023, The National Academies Forum on Drug Discovery, Development, and Translation and Forum on Neuroscience and Nervous System Disorders held a public workshop to examine the diagnosis and treatment of adults with ADHD and explore the challenges and opportunities for the development of new therapeutics. The workshop was supported, in part, through a grant (PAR-23-072) from the Center for Drug Evaluation and Research at the FDA.
Copyright 2024 by the National Academy of Sciences. All rights reserved.
Sections
- The National Academies of SCIENCES • ENGINEERING • MEDICINE
- PLANNING COMMITTEE FOR A WORKSHOP ON ADULT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD): DIAGNOSIS, TREATMENT, AND IMPLICATIONS FOR DRUG DEVELOPMENT
- FORUM ON DRUG DISCOVERY, DEVELOPMENT, AND TRANSLATION
- FORUM ON NEUROSCIENCE AND NERVOUS SYSTEM DISORDERS
- Reviewers
- Acknowledgments
- Acronyms and Abbreviations
- 1. Introduction
- 2. ADHD Diagnosis and Treatment in the United States
- 3. Impact of Misdiagnosis, Bias, and Stigma
- 4. Shared Decision-Making
- 5. Balancing Risks and Benefits of ADHD Treatment for Adults
- 6. Potential Strategies and Implications for Drug Development
- 7. Public Health Considerations and Harm Reduction Strategies
- REFERENCES
- Appendix A. Workshop Agenda
- Appendix B. Biographical Sketches of the Workshop Planning Committee, Speakers, Panelists, and Staff
Publication types
Grants and funding
This activity was supported by contracts between the National Academy of Sciences and Acadia Pharmaceuticals; Alzheimer’s Association; American Brain Coalition; American Neurological Association; Amgen Inc.; Association of American Medical Colleges; AstraZeneca; Biogen; Boehringer Ingelheim (Contract No. 755326); BrightFocus Foundation; Burroughs Wellcome Fund (Contract No. 1023129); California Institute for Regenerative Medicine; Cerevel Therapeutics; Cohen Veterans Bioscience; Department of Veteran Affairs (Contract No. 36C24E20C009); Eisai; Eli Lilly and Company; FasterCures, Milken Institute; Foundation for the National Institutes of Health; Friends of Cancer Research; Gatsby Charitable Foundation; Harmony Biosciences; Janssen Research & Development, LLC; Johnson & Johnson; Karuna Therapeutics; Lundbeck Research USA, Inc.; Medable Inc.; Merck & Co., Inc. (Contract No. MRLCPO-23-166623); Michael J. Fox Foundation for Parkinson’s Research; National Institutes of Health (Contract No. HHSN263201800029I; Task Order Nos. HHSN26300007 and 75N98024F00001): BRAIN Initiative, National Cancer Institute, National Center for Advancing Translational Sciences, National Center for Complementary and Integrative Health, National Eye Institute, National Institute of Allergy and Infectious Diseases, National Institute of Environmental Health Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, and National Institute on Drug Abuse, Office of the Director; National Multiple Sclerosis Society; National Science Foundation; New England Journal of Medicine; One Mind; Paul G. Allen Frontiers Group; Sanofi (Contract No. 77646387); Simons Foundation (Contract No. 995152); Takeda (Contract No. A62909); The George & Anne Ryan Institute for Neuroscience at the University of Rhode Island; U.S. Food and Drug Administration (Contract No. 1R13FD007302-01, Contract No. 1R13FD005362-01, and Contract No. 1R13FD008016); Wellcome Trust. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
LinkOut - more resources
Full Text Sources
Miscellaneous
